Marshall Wace
CADL icon

Marshall Wace’s Candel Therapeutics CADL Stock Holding History

Marshall Wace’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.1M Buy
+300,641
New +$2.27M ﹤0.01% 1607
2025
Q4 		– Sell
-103,847
Closed -$530K – 2992
2025
Q3 		$530K Sell
103,847
-57,633
-36% -$333K ﹤0.01% 2208
2025
Q2 		$817K Sell
161,480
-73,117
-31% -$376K ﹤0.01% 1936
2025
Q1 		$1.33M Buy
+234,597
New +$1.92M ﹤0.01% 1659

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Marshall Wace's CADL Position: Q2 2026 in Review

Marshall Wace opened a new position in Candel Therapeutics (CADL) in Q2 2026: 300,641 shares worth $3.1M. The stake represents ﹤0.01% of the portfolio and ranks #1607 among its holdings. This is a return to the name: Marshall Wace previously reported a position in CADL as recently as Q3 2025.

Marshall Wace first reported a position in CADL in Q1 2025 and has held it in 4 quarters since. 137 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Marshall Wace held 300,641 shares of Candel Therapeutics worth $3.1M as of Q2 2026.
  • Candel Therapeutics was a new Marshall Wace position in Q2 2026.
  • Candel Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1607 holding.
  • Marshall Wace first reported a position in Candel Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 137 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.